{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-006677","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.197443+00:00","generated_at":"2026-06-06T02:27:51.678090+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"AgeX extends convertible note repayment to May 9, 2024 and draws $500K","bullets":["Sixth Amendment to Secured Convertible Promissory Note extends Repayment Date to May 9, 2024.","On Feb 13, 2024, AgeX drew $500,000 from available credit under the Secured Note.","Amendment between AgeX Therapeutics and Juvenescence Limited, effective Feb 9, 2024.","Borrower reaffirms obligations and security interest in collateral; no default continuing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-006677","json":"https://secwatch.observer/filing/0001493152-24-006677.json","markdown":"https://secwatch.observer/filing/0001493152-24-006677.md","text":"https://secwatch.observer/filing/0001493152-24-006677.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224006677/0001493152-24-006677-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224006677/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:27:51.678090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3889a5a446c26897d5ea74fe75363bde98b0a8f9","claim":"Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited maturing May 9, 2024.","evidence_excerpt":"On February 13, 2024, AgeX drew $500,000 of its credit available from Juvenescence under the Secured Note. The Repayment Date on which the outstanding principal balance of the Secured Note will become due and payable shall be May 9, 2024.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224006677/0001493152-24-006677-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$500,000"},{"label":"Counterparty","value":"Juvenescence Limited"},{"label":"Maturity","value":"May 9, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"ba8a3e29963b5c74b8fdbeca580954db5e339071","claim":"Serina Therapeutics, Inc. amended Sixth Amendment to Amended and Restated Convertible Promissory Note with Juvenescence Limited (effective 2024-02-09).","evidence_excerpt":"On February 9, 2024, AgeX and Juvenescence Limited (“Juvenescence”) executed a Sixth Amendment to Amended and Restated Convertible Promissory Note (the “Amendment”) that extends to May 9, 2024 the “Repayment Date” on which the outstanding principal balance and accrued loan origination fees will become due and payable pursuant to the Amended and Restated Secured Convertible Promissory Note, dated February 9, 2023, as previously amended, modified, and restated (the “Secured Note”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224006677/0001493152-24-006677-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Juvenescence Limited"},{"label":"Effective","value":"2024-02-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}